[{"id":"28335d77-d098-4529-a1f0-51404005b2f4","acronym":"MK-1454-001","url":"https://clinicaltrials.gov/study/NCT03010176","created_at":"2021-01-29T07:13:56.449Z","updated_at":"2024-07-02T16:35:17.664Z","phase":"Phase 1","brief_title":"Study of Ulevostinag (MK-1454) Alone or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)","source_id_and_acronym":"NCT03010176 - MK-1454-001","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ulevostinag (MK-1454)"],"overall_status":"Completed","enrollment":" Enrollment 156","initiation":"Initiation: 02/03/2017","start_date":" 02/03/2017","primary_txt":" Primary completion: 04/21/2022","primary_completion_date":" 04/21/2022","study_txt":" Completion: 04/21/2022","study_completion_date":" 04/21/2022","last_update_posted":"2024-02-26"},{"id":"a94bcbe4-e3f2-4d93-8686-baa0f53394db","acronym":"MK-1454-002","url":"https://clinicaltrials.gov/study/NCT04220866","created_at":"2021-01-18T20:32:40.942Z","updated_at":"2024-07-02T16:35:31.362Z","phase":"Phase 2","brief_title":"Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)","source_id_and_acronym":"NCT04220866 - MK-1454-002","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • ulevostinag (MK-1454)"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 03/04/2020","start_date":" 03/04/2020","primary_txt":" Primary completion: 09/30/2022","primary_completion_date":" 09/30/2022","study_txt":" Completion: 09/30/2022","study_completion_date":" 09/30/2022","last_update_posted":"2023-10-27"}]